Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Mutant Heat Shock Protein Vaccine Prevents Vitiligo in Mouse Model

By BiotechDaily International staff writers
Posted on 11 Mar 2013
Image: Mice that have developed vitiligo (Photo courtesy of Loyola University Chicago Stritch School of Medicine).
Image: Mice that have developed vitiligo (Photo courtesy of Loyola University Chicago Stritch School of Medicine).
Image: Vitiligo mice after vaccination with mutant HSP70i protein (Photo courtesy of Loyola University Chicago Stritch School of Medicine).
Image: Vitiligo mice after vaccination with mutant HSP70i protein (Photo courtesy of Loyola University Chicago Stritch School of Medicine).
An experimental vaccine based on a genetically modified form of inducible heat shock protein 70 (HSP70i) prevented onset and partially cured vitiligo in a mouse model of the disease.

Vitiligo is skin disorder manifested by smooth, white spots on various parts of the body. Though melanocytes, the pigment-making cells of the skin, are structurally intact, they have lost the ability to synthesize the pigment. The reason for the condition is unclear although research suggests that it may arise from autoimmune, genetic, oxidative stress, neural, or viral causes. Individuals with vitiligo (about 1% of the adult population) are usually in good general health, but vitiligo presents a cosmetic problem that can be serious in dark-skinned individuals. Normal skin color rarely returns, and there is no known cure.

Investigators at Loyola University (Chicago, IL, USA) had shown previously that HSP70i played a vital role in the autoimmune response that causes vitiligo. In the current work they genetically modified one of HSP70i's 641 amino acids to create a mutant HSP70i molecule.

The investigators reported in the February 27, 2013, issue of the journal Science Translational Medicine that a vaccine based on the DNA encoding for mutant HSP70i applied months before spontaneous depigmentation prevented vitiligo in mice expressing a transgenic, melanocyte-reactive T-cell receptor. Furthermore, use of mutant HSP70i therapeutically in a different, rapidly depigmenting model after loss of differentiated melanocytes resulted in 76% recovery of pigmentation. Treatment also prevented relevant T-cells from populating mouse skin.

In addition to the dramatic results seen in the mouse model, “The mice look normal,” said senior author Dr. I. Caroline Le Poole, professor of pathology, microbiology, and immunology at Loyola University. Some of the beneficial effects of mutant HSP70i were seen in cultures grown from human vitiligo skin specimens.

Related Links:
Loyola University



Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.